Meanwhile, Novo Nordisk's (NYSE: NVO) obesity franchise made the Denmark-based drugmaker 82.3 billion Danish krone (roughly ...

The goal of the Novo Nordisk Foundation and DTU's major new research initiative is ambitious: to strengthen Denmark and Europe's bioeconomy and ...

Novo Nordisk’s shares tumbled 18percent and were on track for their biggest one-day drop since July 2025. The Danish company ...

Buy despite FY2026 headwinds, pricing pressure, and margin risks. Click for this NVO earnings update and why I am bullish.

Novo Nordisk says the expiration of its patents for some semaglutide GLP-1 drug treatments in markets like Canada will result ...

The share price of Novo Nordisk (NYSE: NVO) plunged by nearly 15% on Tuesday after the company posted sales and earnings ...

The California-based biotech company's quarterly revenue rose 9% from a year earlier to $9.9 billion, which beat the average ...

The once high-flying Danish drugmaker has struggled to fend off rivals in the weight-loss industry, especially Eli Lilly, ...

In contrast to Lilly’s optimistic forecasts, Novo cited pricing constraints and competitive pressure in predicting up to a 13 ...

Novo Nordisk hires former Optum exec Jamey Millar as executive vice president of U.S. operations, effective Feb. 5, 2024.

Danish obesity drug maker Novo Nordisk's new CEO risks being on the losing side of a damaging price war as "unprecedented" ...

Shares of Novo Nordisk dropped roughly 18% in Denmark after the Ozempic and Wegovy maker warned that sales would decline more ...